{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:39:04Z","timestamp":1792834744065,"version":"4.5.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Amylin is a pancreatic neuroendocrine peptide that links peripheral metabolic regulation with central homeostatic and neurodegenerative pathways. However, its relevance to the inflammatory and demyelinating processes underlying multiple sclerosis (MS) remains unclear. To date, the role of amylin in MS has not been investigated. This study investigated serum amylin levels in patients with MS and their association with disease status. This cross-sectional case-control study included 62 patients meeting the 2017 McDonald criteria for MS and 63 control participants without MS or associated risk factors. Serum amylin levels were measured using enzyme-linked immunosorbent assay (ELISA). Between-group and phenotype-specific differences were examined. Multivariable logistic regression and receiver operating characteristic (ROC) curve analyses were performed to assess the association between serum amylin and MS status, and the discriminatory performance of serum amylin, respectively. Serum amylin levels were determined in both groups and reported as mean values. Mean serum amylin levels were significantly lower in patients with MS than in controls (234.01\u2005\u00b1\u200594.84 vs 284.04\u2005\u00b1\u2005110.02\u2009ng\/L;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.003). The groups were comparable across the principal anthropometric, metabolic, and biochemical variables assessed. No significant differences were observed among the relapsing\u2013remitting, secondary progressive, and primary progressive MS (PPMS) phenotypes; however, pairwise analysis demonstrated a significant difference between the relapsing\u2013remitting MS (RRMS) subgroup and controls (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.017). In multivariable analysis, higher serum amylin levels remained independently associated with lower odds of MS after adjustment for aspartate aminotransferase (AST) activity (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.02). Despite the significant between-group difference, serum amylin demonstrated only modest discriminatory performance (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.003). Lower circulating amylin levels were associated with MS status, although their modest discriminatory performance does not support the use of serum amylin as a standalone diagnostic marker, based on the present data. The phenotype-specific difference observed in RRMS warrants further investigation in larger, longitudinal, and clinically characterized cohorts. These findings may deepen insights into MS development and support future biomarker research.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050425","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:00:38Z","timestamp":1787968838000},"page":"e50425","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Serum amylin levels in patients with multiple sclerosis"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1292-1144","authenticated-orcid":false,"given":"Ufuk","family":"Cinkir","sequence":"first","affiliation":[{"name":"Department of Neurology, Ankara Medipol University School of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3226-3756","authenticated-orcid":false,"given":"Levent Sinan","family":"Bir","sequence":"additional","affiliation":[{"name":"Department of Neurology, Pamukkale University School of Medicine, Denizli, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1999-0510","authenticated-orcid":false,"given":"Selma","family":"Tekin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Pamukkale University School of Medicine, Denizli, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5218-3983","authenticated-orcid":false,"given":"Ahmet Magrur","family":"Karagulmez","sequence":"additional","affiliation":[{"name":"Department of Neurology, Servergazi State Hospital, Denizli, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9173-0142","authenticated-orcid":false,"given":"Esin","family":"Avci Cicek","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Pamukkale University School of Medicine, Denizli, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6395-7924","authenticated-orcid":false,"given":"Hande","family":"Senol","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Pamukkale University School of Medicine, Denizli, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261024","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(10)70064-8","article-title":"The changing demographic pattern of multiple sclerosis epidemiology.","volume":"9","author":"Koch-Henriksen","year":"2010","journal-title":"Lancet Neurol"},{"key":"R3-20261024","first-page":"1","article-title":"Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy.","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Cell J"},{"key":"R4-20261024","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis.","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med"},{"key":"R5-20261024","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/bph.13496","article-title":"Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development.","volume":"173","author":"Bower","year":"2016","journal-title":"Br J Pharmacol"},{"key":"R6-20261024","doi-asserted-by":"crossref","first-page":"2798269","DOI":"10.1155\/2016\/2798269","article-title":"Islet amyloid polypeptide: structure, function, and pathophysiology.","volume":"2016","author":"Akter","year":"2016","journal-title":"J Diabetes Res"},{"key":"R7-20261024","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/bph.15605","article-title":"Beyond CGRP: the calcitonin peptide family as targets for migraine and pain.","volume":"179","author":"Rees","year":"2022","journal-title":"Br J Pharmacol"},{"key":"R8-20261024","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.3390\/jcm11082207","article-title":"Mediators of amylin action in metabolic control.","volume":"11","author":"Boyle","year":"2022","journal-title":"J Clin Med"},{"key":"R9-20261024","doi-asserted-by":"crossref","first-page":"320","DOI":"10.7570\/jomes21071","article-title":"Amylin as a future obesity treatment.","volume":"30","author":"Dehestani","year":"2021","journal-title":"J Obes Metab Syndr"},{"key":"R10-20261024","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s13300-025-01733-8","article-title":"Amylin: from mode of action to future clinical potential in diabetes and obesity.","volume":"16","author":"Vol\u010dan\u0161ek","year":"2025","journal-title":"Diabetes Ther"},{"key":"R11-20261024","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0306-3623(97)00442-4","article-title":"Amylin and gastrointestinal activity.","volume":"31","author":"Guidobono","year":"1998","journal-title":"Gen Pharmacol"},{"key":"R12-20261024","doi-asserted-by":"crossref","first-page":"e1480","DOI":"10.1096\/fba.2024-00151","article-title":"The role of amylin, a gut-brain axis hormone, in metabolic and neurological disorders.","volume":"7","author":"Muhammad","year":"2025","journal-title":"FASEB Bioadv"},{"key":"R13-20261024","doi-asserted-by":"crossref","first-page":"R605","DOI":"10.1152\/ajpregu.2001.280.3.R605","article-title":"Comparative effects of amylin and cholecystokinin on food intake and gastric emptying in rats.","volume":"280","author":"Reidelberger","year":"2001","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R14-20261024","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3389\/fnagi.2019.00225","article-title":"High-fat diet increases amylin accumulation in the hippocampus and accelerates brain aging in hIAPP transgenic mice.","volume":"11","author":"Xi","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"R15-20261024","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.physbeh.2011.04.044","article-title":"Influence of high-fat feeding, diet-induced obesity, and hyperamylinemia on the sensitivity to acute amylin.","volume":"104","author":"Boyle","year":"2011","journal-title":"Physiol Behav"},{"key":"R16-20261024","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.physbeh.2011.02.015","article-title":"Amylinergic control of food intake in lean and obese rodents.","volume":"105","author":"Boyle","year":"2011","journal-title":"Physiol Behav"},{"key":"R17-20261024","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0196-9781(94)00203-I","article-title":"Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin.","volume":"16","author":"Lutz","year":"1995","journal-title":"Peptides"},{"key":"R18-20261024","first-page":"R1777","article-title":"Anorectic effect of amylin is not transmitted by capsaicin-sensitive nerve fibers.","volume":"274","author":"Lutz","year":"1998","journal-title":"Am J Physiol"},{"key":"R19-20261024","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0196-9781(97)00292-1","article-title":"Lesion of the area postrema\/nucleus of the solitary tract (AP\/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats.","volume":"19","author":"Lutz","year":"1998","journal-title":"Peptides"},{"key":"R20-20261024","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.regpep.2008.03.010","article-title":"Gastric emptying in response to IAPP and CCK in rats with subdiaphragmatic afferent vagotomy.","volume":"148","author":"Wickbom","year":"2008","journal-title":"Regul Pept"},{"key":"R21-20261024","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1111\/ejn.12672","article-title":"The role of the area postrema in the anorectic effects of amylin and salmon calcitonin: behavioral and neuronal phenotyping.","volume":"40","author":"Braegger","year":"2014","journal-title":"Eur J Neurosci"},{"key":"R22-20261024","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0306-4522(94)90388-3","article-title":"In vitro autoradiographic localization of amylin binding sites in rat brain.","volume":"62","author":"Sexton","year":"1994","journal-title":"Neuroscience"},{"key":"R23-20261024","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.physbeh.2004.01.006","article-title":"Infusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats.","volume":"81","author":"Mollet","year":"2004","journal-title":"Physiol Behav"},{"key":"R24-20261024","doi-asserted-by":"crossref","first-page":"112040","DOI":"10.1016\/j.isci.2025.112040","article-title":"From the pancreas to the amygdala: New brain area critical for ingestive and motivated behavior control exerted by amylin.","volume":"28","author":"Byun","year":"2025","journal-title":"iScience"},{"key":"R25-20261024","doi-asserted-by":"crossref","first-page":"102313","DOI":"10.1016\/j.molmet.2025.102313","article-title":"Pancreatic amylin dynamically reconfigures distributed brain networks governing appetite regulation in mice.","volume":"103","author":"Gezginer","year":"2026","journal-title":"Mol Metab"},{"key":"R26-20261024","doi-asserted-by":"crossref","first-page":"100011","DOI":"10.1016\/j.addicn.2022.100011","article-title":"Actions of feeding-related peptides on the mesolimbic dopamine system in regulation of natural and drug rewards.","volume":"2","author":"Dunigan","year":"2022","journal-title":"Addict Neurosci"},{"key":"R27-20261024","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1055\/a-1749-4852","article-title":"Obesity - a matter of motivation?","volume":"130","author":"Hanssen","year":"2022","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"R28-20261024","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fnins.2015.00216","article-title":"Amylin at the interface between metabolic and neurodegenerative disorders.","volume":"9","author":"Lutz","year":"2015","journal-title":"Front Neurosci"},{"key":"R29-20261024","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0014-5793(95)01512-4","article-title":"Effects of beta cell granule components on human islet amyloid polypeptide fibril formation.","volume":"379","author":"Westermark","year":"1996","journal-title":"FEBS Lett"},{"key":"R30-20261024","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00125-006-0206-7","article-title":"Intracellular amyloid-like deposits contain unprocessed pro-islet amyloid polypeptide (proIAPP) in beta cells of transgenic mice overexpressing the gene for human IAPP and transplanted human islets.","volume":"49","author":"Paulsson","year":"2006","journal-title":"Diabetologia"},{"key":"R31-20261024","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.devcel.2015.01.022","article-title":"Cellular functions of the amyloid precursor protein from development to dementia.","volume":"32","author":"van der Kant","year":"2015","journal-title":"Dev Cell"},{"key":"R32-20261024","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of alzheimer\u2019s disease: progress and problems on the road to therapeutics.","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"R33-20261024","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","article-title":"The amyloid cascade hypothesis for alzheimer\u2019s disease: an appraisal for the development of therapeutics.","volume":"10","author":"Karran","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"R34-20261024","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5607\/en23014","article-title":"Advances in amyloid-\u03b2 clearance in the brain and periphery: implications for neurodegenerative diseases.","volume":"32","author":"Ullah","year":"2023","journal-title":"Exp Neurobiol"},{"key":"R35-20261024","doi-asserted-by":"crossref","first-page":"101999","DOI":"10.1016\/j.arr.2023.101999","article-title":"Insulin-degrading enzyme: Roles and pathways in ameliorating cognitive impairment associated with alzheimer\u2019s disease and diabetes.","volume":"90","author":"Tian","year":"2023","journal-title":"Ageing Res Rev"},{"key":"R36-20261024","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1007\/s10571-023-01365-1","article-title":"Roles of ApoE4 on the pathogenesis in alzheimer\u2019s disease and the potential therapeutic approaches.","volume":"43","author":"Sun","year":"2023","journal-title":"Cell Mol Neurobiol"},{"key":"R37-20261024","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/molecules27031021","article-title":"Molecular mechanisms of amylin turnover, misfolding and toxicity in the pancreas.","volume":"27","author":"Bhowmick","year":"2022","journal-title":"Molecules"},{"key":"R38-20261024","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ana.23956","article-title":"Amylin deposition in the brain: a second amyloid in Alzheimer disease?","volume":"74","author":"Jackson","year":"2013","journal-title":"Ann Neurol"},{"key":"R39-20261024","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.3390\/ijms21093165","article-title":"Type 3 diabetes and its role implications in Alzheimer\u2019s disease.","volume":"21","author":"Nguyen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R40-20261024","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajpath.2014.11.016","article-title":"In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease.","volume":"185","author":"Oskarsson","year":"2015","journal-title":"Am J Pathol"},{"key":"R41-20261024","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/mp.2014.17","article-title":"Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer\u2019s disease.","volume":"20","author":"Zhu","year":"2015","journal-title":"Mol Psychiatry"},{"key":"R42-20261024","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.neurobiolaging.2013.10.076","article-title":"Neuroprotective effects of the amylin analogue pramlintide on Alzheimer\u2019s disease pathogenesis and cognition.","volume":"35","author":"Adler","year":"2014","journal-title":"Neurobiol Aging"},{"key":"R43-20261024","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fnagi.2013.00038","article-title":"Lessons from two prevalent amyloidoses-what amylin and A\u03b2 have in common.","volume":"5","author":"G\u00f6tz","year":"2013","journal-title":"Front Aging Neurosci"},{"key":"R44-20261024","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/00005344-199512000-00012","article-title":"Amylin-induced relaxation of the perfused mesenteric arterial bed: meditation by calcitonin gene-related peptide receptors.","volume":"26","author":"Westfall","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"R45-20261024","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1100\/tsw.2001.23","article-title":"Amylin: localization, effects on cerebral arteries and on local cerebral blood flow in the cat.","volume":"1","author":"Edvinsson","year":"2001","journal-title":"Sci World J"},{"key":"R46-20261024","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.3390\/ijms26146693","article-title":"Understanding the insulin-degrading enzyme: a new look at alzheimer\u2019s disease and a\u03b2 plaque management.","volume":"26","author":"Cerasuolo","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R47-20261024","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3390\/cimb45020094","article-title":"Multiple sclerosis: inflammatory and neuroglial aspects.","volume":"45","author":"Papiri","year":"2023","journal-title":"Curr Issues Mol Biol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:00:33Z","timestamp":1792832433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050425"}},"subtitle":["A cross-sectional case-control study"],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":46,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050425","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"2024-12-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}